Search

Summary: Background: Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. Aim: To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. Methods: The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. Results: After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow‐up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self‐regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar‐like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. Conclusion: LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas. [ABSTRACT FROM AUTHOR]

Primary cutaneous T-cell lymphomas showing Gamma-Delta ( ) phenotype and predominantly Epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous T-cell lymphomas. The last patient (n°4) experienced an ENT relapse (palate ulceration) after 42 months of remission under methotrexate. Cutaneous gamma delta T-cell lymphomas (CGDTCL) are rare lymphomas representing <1% of all cutaneous lymphomas, globally associated with a decreased overall survival.1,2 CGDTCL are a defined entity of the 2018 EORTC-WHO classification, most often presenting as nodules or infiltrated plaques, but mycosis fungoides-like3 and pagetoid reticulosis-like presentations have also been reported.4 The prognosis is generally poor.5,6 A few indolent cases have been reported.1,7-9 The clinical presentation of such indolent PCGDTCL has been poorly described. [Extracted from the article]

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study Immune checkpoint inhibitors (ICI), most commonly anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) therapies, have revolutionized the treatment of many cancers. We thank Dr C-J. Clerc (Niort), Dr E. Funck-Brentano (Paris), Dr D. Giacchero (Nice), Pr L. Mortier (Lille), Dr M. Dinulescu (Rennes), Pr L. Boussemart (Nantes), Pr L. Machet (Tours), Dr S. Duvert-Lehembre (Dunkerque), Dr A. Viarnaud (Paris), Dr C. Joachim (Amiens), Dr C. Bara (Le Mans), Dr E. Baubion (Fort de France), Dr B. Bergeret (Nîmes), Dr F. Brunet-Possenti (Paris), Dr S. Debarbieux (Lyon), Dr V. Hebert (Rouen), Pr Grange (Reims), Dr M-P. Konstantinou (Toulouse), Dr A. Marzouki-Zerouali (Nancy), Dr J. Moreau-Huguen (Lorient), Dr C. Phan (Argenteuil), Dr I. Templier (Grenoble), Dr P. Celerier (la Rochelle), Pr F. Aubin (Besançon), P. Modiano (Lille), Dr L. Dousset (Bordeaux), Dr J. Bonini (Bordeaux) for providing us patient data and for their assistance in the preparation of the manuscript. [Extracted from the article]

Abstract: Background: Identification of myositis‐specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody‐associated clinical phenotype. Objective: We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA. Methods: A 3.5‐year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis. Results: MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation‐associated protein‐5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor‐1 antibodies (11.1%), antinuclear matrix protein‐2 antibodies (6.8%) and antiaminoacyl‐transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1). Conclusion: Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis. [ABSTRACT FROM AUTHOR]

Dear Editor, Controversy exists regarding the risk and prognosis of lymphomas during treatment with biologics.[1] Risk evaluation must consider the underlying medical condition - as chronic inflammatory diseases are associated with an excess risk of lymphoma[[2]] - and ongoing treatments (azathioprine, ciclosporin).[[4]] To date, a few isolated cases and two small series of primary cutaneous lymphoma (PCL) - mostly mycosis fungoides (MF) - have been reported in patients treated with biologics.[[6]] Our aim was to describe PCL in patients during treatment with biologics from two national registries in order to evaluate their behaviour and to propose management recommendations. Fifteen patients with CTCL had a past of benign dermatosis, eczema or psoriasis, confirmed by skin biopsy in six patients (including one with T-MF). Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. [Extracted from the article]

Skin fibroblasts from 18 scleroderma patients were seeded into collagen lattices and their ability to retract their substratum was compared with that of control fibroblasts from healthy donors. When considered as a whole, scleroderma fibroblasts retracted lattices earlier and more intensely than controls. Analysis of individual results demonstrated that morphea and diffuse systemic sclerosis (dSSc) fibroblasts had different kinetics of lattice retraction. Fibroblasts which contracted lattices more intensely than controls were found to produce increased levels of fibronectin. A comparison of the retraction of collagen lattices by fibroblasts from involved (IS) and uninvolved skin (US) of the same patients (n = 4) showed that those from IS retracted the lattices more than fibroblasts from normal donors, whereas a high variabilty was found with fibroblasts from US. The increased retraction of collagen lattices seems to be a feature of the more severe forms of scleroderma. [ABSTRACT FROM AUTHOR]

Sixteen patients with localized scleroderma (LS) and 11 with progressive systemic sclerosis (PSS) were studied using non-invasive techniques to determine skin thickness, skin extensibility, transcutaneous PO2 and cutaneous blood flow and were compared with normal controls. LS was characterized by a decreased skin extensibility with thickening of the skin in progressive lesions. There was an increase in the cutaneous microcirculation with a decrease in the POT. In PSS, there was a decrease in the skin extensibility caused by thickening of the skin, but no change in cutaneous microcirculation or PO2 values. These results indicate that skin thickness and extensibility are the most useful parameters in the study of the progression of LS and PSS. [ABSTRACT FROM AUTHOR]

Dear Editor, Tumour necrosis factor (TNF) inhibitors are used to treat a range of chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. In two recent large cohorts of patients with inflammatory bowel disease treated with TNF inhibitors ( I n i = 1315), skin infections were the most common dermatological complication, with a prevalence of 12-13-5%.[[1]] Among these patients, 22 cases (1-7%) were labelled as having staphylococcal nasal infection. [Extracted from the article]